The United States of America, As Represented by the Secretary, Department of Health and Human Services

Atsushi Kitani

Warren Strober

Ivan J Fuss

Peter Mannon

Raj K Puri

Koji Kawakami

Markus F Neurath

Kazuhiko Nakamura

Stefan Fichtner-Feigl

Tetsuya Takagawa

Tomohiro Watanabe

Jan Preiss

Stefan Universität Regensburg Abteilung Für Chirurgie Fichtner-Feigl

Raj Puri

Disclosed are methods of treating or preventing an intestinal disease or disorder comprising administering to a subject a modulator of leucine rich repeat kinase 2 (LRRK2) in an amount effective to treat or prevent an intestinal disease or disorder and methods of determining the susceptibility or risk of a subject to develop an intestinal disease.

Treatment or prevention of an intestinal disease or disorder

The present invention provides a method of treating or preventing the inflammatory response of ulcerative colitis or Crohn's disease in a subject comprising administering to the subject an effective amount of a substance that inhibits the binding of IL-13 to IL-13 receptors on NKT cells or delivers an effector molecule to the NKT cells.

Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells

The present invention provides a method of treating or preventing inflammation in a subject comprising administering to the subject an effective amount of a muramyl dipeptide (MDP).

Use of muramyl dipeptide (MDP) for treating inflammation

The present invention provides alternatives to traditional drug and surgical treatments for IBD. In particular, the present invention provides compositions and methods for the treatment of autoimmune diseases such as IBD in humans using TGF-&#x3b2; therapy. The compositions of the present invention provide vectors containing TGF-&#x3b2; under the control of an inducible promoter. In particularly preferred embodiments, the present invention provides regulated plasmid constructs capable of inducing TGF-&#x3b2; production. In preferred embodiments, the methods of the present invention utilize the vectors described for assaying the expression of a gene in a cell. In some preferred embodiments, the methods of the present invention utilize the administration of TGF-&#x3b2; containing vectors to treat IBD. In alternative preferred embodiments, the present invention provides methods and compositions for the induction of high-level interleukin (e.g., IL-10) production.

Inducible plasmid vector encoding TGF-&#x3b2; and use thereof

The present invention provides a method of treating or preventing the inflammatory response of an inflammatory bowel disease in a subject, comprising administering to the subject an amount of a STAT-4 antisense oligonucleotide effective in treating or preventing the inflammatory response of the inflammatory bowel disease.

Methods of treating colitis using STAT-4 anti-sense oligonucleotides

Growing community of inventors

Rockville, MD, United States of America

Atsushi Kitani